

NC MEDICAID and NC HEALTH CHOICE DIVISION OF HEALTH BENEFITS PREFERRED DRUG LIST REVIEW PANEL MEETING

AGENDA

Thursday, January 13, 2022 9:00 a.m. – 3:00 p.m. Virtual Online Meeting

- I. Welcome
- II. Introductions / Medicaid Updates
- III. Overview of Panel Activities and Procedures
- IV. Drug Class Reviews, Review of Public Comments and Public Testimony

NC Medicaid is beginning a new PDL Panel meeting policy in 2022. We will be moving to meeting two times per year (January and July), in addition to reviewing every PDL category at least once per calendar year. Public comments during the 45-day public comment period will still only be allowed for categories the State designates on the publicly posted document. Speakers at the PDL Panel meeting are only allowed for categories listed in the agenda for that meeting. The categories that are highlighted below are categories that have no State recommendations but are open for discussion. The following are considered the open categories for the 1/13/2022 meeting:

ALZHEIMER'S AGENTS

ANALGESICS

- 1. Opioid Long-Acting
- 2. Short-Acting Schedule III-IV Opioids and Opioid/Analgesic Combinations
- 3. NSAIDS
- 4. Neuropathic Pain

ANTICONVULSANTS

1. Second Generation

ANTI-INFECTIVES, SYSTEMIC

- 1. Lincosamides and Oxazolidinones
- 2. Nitromidazoles
- 3. Antifungals
- 4. Antivirals, Influenza

BEHAVIORAL HEALTH

- 1. Antidepressants, Other
- 2. Antihyperkinesis / ADHD
- 3. Antipsychotics; Injectable, Long-Acting
- 4. Atypical Antipsychotics; Oral / Topical

CARDIOVASCULAR

- 1. ACE Inhibitors
- 2. Beta Blockers
- 3. Coronary Vasodilators
- 4. Triglyceride Lowering Agents

CENTRAL NERVOUS SYSTEM

- 1. Antimigraine Agents
- 2. CGRP Blockers/Modulators PREVENTATIVE (New Category)
- 3. CGRP Blockers/Modulators ACUTE TREATMENT (New Category)
- 4. Anti-Parkinson and Restless Leg Syndrome Agents
- 5. Multiple Sclerosis, Oral
- 6. Sedative Hypnotics
- 7. Smoking Cessation

ENDOCRINOLOGY

- 1. Hypoglycemics; Injectable, Short-Acting Insulin
- 2. Hypoglycemics; Injectable, Long-Acting Insulin

GASTROINTESTINAL

- 1. Antiemetic and Antivertigo Agents
- 2. Bile Acid Salts
- 3. Selective Constipation Agents

GENITOURINARY/RENAL

1. Urinary Antispasmodics

HEMATOLOGIC

1. Colony Stimulating Factors

OPHTHALMIC

- 1. Allergic Conjunctivitis Agents
- 2. Antibiotics
- 3. Antibiotics-Steroid Combinations
- 4. Anti-Inflammatory
- 5. Anti-Inflammatory / Immunomodulator
- 6. Alpha 2 Adrenergic Agents
- 7. Beta Blocker Agents / Combinations
- 8. Carbonic Anhydrase Inhibitors / Combinations
- 9. Prostaglandin Agonists

10. Rho Kinase Modifiers / Combinations

OSTEOPOROSIS

1. Bone Resorption Suppression and Related Agents

OTIC

- 1. Antibiotics
- 2. Anti-Infectives and Anesthetics
- 3. Anti-Inflammatory

RESPIRATORY

- 1. Beta-Adrenergic Handheld, Long-Acting
- 2. Beta-Adrenergic Handheld, Short-Acting
- 3. Beta-Adrenergic, Nebulizer Agents
- 4. Beta-Adrenergic, Oral
- 5. Orally Inhaled Anticholinergics / COPD Agents
- 6. Inhaled Corticosteroids
- 7. Inhaled Corticosteroid Combinations
- 8. Intranasal Rhinitis Agents
- 9. Leukotriene Modifiers
- 10. Low Sedating Antihistamines
- 11. Low Sedating Antihistamine Combinations

TOPICALS

- 1. Acne Agents
- 2. Androgenic Agents
- 3. NSAIDs
- 4. Antibiotics
- 5. Antibiotics- Vaginal
- 6. Antifungals
- 7. Antiparasitics
- 8. Antivirals
- 9. Immunomodulators, Atopic Dermatitis
- 10. Imidazoquinolinamines
- 11. Psoriasis
- 12. Rosacea Agents
- 13. Steroids, Low Potency
- 14. Steroids, Medium Potency
- 15. Steroids, High Potency
- 16. Steroids, Very High Potency

MISCELLANEOUS

- 1. Antipsoriatics, Oral
- 2. Epinephrine, Self-Injected
- 3. Estrogen Agents, Combinations
- 4. Progestational Agents

- 5. Estrogen Agents, Oral / Transdermal
- 6. Estrogen Agents, Vaginal Preparations
- 7. Glucocorticoid Steroids, Oral
- 8. Immunomodulators, Systemic
- 9. Immunosuppressants
- 10. Movement Disorders
- 11. Opioid Antagonists
- 12. Opioid Dependence
- 13. Skeletal Muscle Relaxants
- 14. Disposable Insulin Delivery Devices

DIABETIC CONTINUOUS GLUCOSE MONITOR SUPPLIES

- 1. Continuous Glucose Monitor Transmitters / Receivers / Readers
- 2. Continuous Glucose Monitor Sensors

DIABETIC SUPPLIES

VARIOUS MEDICATIONS REMOVED FROM COVERAGE

V. Closing comments and adjournment